303 related articles for article (PubMed ID: 30219366)
1. ICOSL-augmented adenoviral-based vaccination induces a bipolar Th17/Th1 T cell response against unglycosylated MUC1 antigen.
Carrell RK; Stanton RA; Ethier SP; LaRue AC; Soloff AC
Vaccine; 2018 Oct; 36(42):6262-6269. PubMed ID: 30219366
[TBL] [Abstract][Full Text] [Related]
2. Intradermal vaccination of MUC1 transgenic mice with MUC1/IL-18 plasmid DNA suppresses experimental pulmonary metastases.
Shi FF; Gunn GR; Snyder LA; Goletz TJ
Vaccine; 2007 Apr; 25(17):3338-46. PubMed ID: 17292519
[TBL] [Abstract][Full Text] [Related]
3. Antitumor effect of adenoviral vector prime protein boost immunity targeting the MUC1 VNTRs.
Wang Y; Liu C; Xia Q; Wang P; Li B; Lu Z; Sun J; Wu H; Yu B; Wu J; Yu X; Kong W; Zhang H; Cong X
Oncol Rep; 2014 Mar; 31(3):1437-44. PubMed ID: 24378623
[TBL] [Abstract][Full Text] [Related]
4. Th1 cytokine responses fail to effectively control Chlamydia lung infection in ICOS ligand knockout mice.
Kadkhoda K; Wang S; Joyee AG; Fan Y; Yang J; Yang X
J Immunol; 2010 Apr; 184(7):3780-8. PubMed ID: 20190137
[TBL] [Abstract][Full Text] [Related]
5. Optimal TLR9 signal converts tolerogenic CD4-8- DCs into immunogenic ones capable of stimulating antitumor immunity via activating CD4+ Th1/Th17 and NK cell responses.
Zhang X; Munegowda MA; Yuan J; Wei Y; Xiang J
J Leukoc Biol; 2010 Aug; 88(2):393-403. PubMed ID: 20466823
[TBL] [Abstract][Full Text] [Related]
6. Tumor regression by CD4 T-cells primed with dendritic/tumor fusion cell vaccines.
Koido S; Enomoto Y; Apostolopoulos V; Gong J
Anticancer Res; 2014 Aug; 34(8):3917-24. PubMed ID: 25075013
[TBL] [Abstract][Full Text] [Related]
7. Three different vaccines based on the 140-amino acid MUC1 peptide with seven tandemly repeated tumor-specific epitopes elicit distinct immune effector mechanisms in wild-type versus MUC1-transgenic mice with different potential for tumor rejection.
Soares MM; Mehta V; Finn OJ
J Immunol; 2001 Jun; 166(11):6555-63. PubMed ID: 11359807
[TBL] [Abstract][Full Text] [Related]
8. ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells.
Guedan S; Chen X; Madar A; Carpenito C; McGettigan SE; Frigault MJ; Lee J; Posey AD; Scholler J; Scholler N; Bonneau R; June CH
Blood; 2014 Aug; 124(7):1070-80. PubMed ID: 24986688
[TBL] [Abstract][Full Text] [Related]
9. ADAM10-Mediated ICOS Ligand Shedding on B Cells Is Necessary for Proper T Cell ICOS Regulation and T Follicular Helper Responses.
Lownik JC; Luker AJ; Damle SR; Cooley LF; El Sayed R; Hutloff A; Pitzalis C; Martin RK; El Shikh MEM; Conrad DH
J Immunol; 2017 Oct; 199(7):2305-2315. PubMed ID: 28814605
[TBL] [Abstract][Full Text] [Related]
10. Role and plasticity of Th1 and Th17 responses in immunity to
Ferraro A; Buonocore SM; Auquier P; Nicolas I; Wallemacq H; Boutriau D; van der Most RG
Hum Vaccin Immunother; 2019; 15(12):2980-2992. PubMed ID: 31149870
[TBL] [Abstract][Full Text] [Related]
11. Inducible co-stimulatory molecule ligand is protective during the induction and effector phases of crescentic glomerulonephritis.
Odobasic D; Kitching AR; Semple TJ; Holdsworth SR
J Am Soc Nephrol; 2006 Apr; 17(4):1044-53. PubMed ID: 16540559
[TBL] [Abstract][Full Text] [Related]
12. [Dynamic alteration of CD154/CD40 and its effects on Th1/Th2 polarization in inducible co-stimulator ligand knockout mice infected with Schistosoma japonicum].
Wang Y; Xia CM
Beijing Da Xue Xue Bao Yi Xue Ban; 2015 Dec; 47(6):898-904. PubMed ID: 26679647
[TBL] [Abstract][Full Text] [Related]
13. Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine.
Lakshminarayanan V; Thompson P; Wolfert MA; Buskas T; Bradley JM; Pathangey LB; Madsen CS; Cohen PA; Gendler SJ; Boons GJ
Proc Natl Acad Sci U S A; 2012 Jan; 109(1):261-6. PubMed ID: 22171012
[TBL] [Abstract][Full Text] [Related]
14. Autologous MUC1-specific Th1 effector cell immunotherapy induces differential levels of systemic TReg cell subpopulations that result in increased ovarian cancer patient survival.
Dobrzanski MJ; Rewers-Felkins KA; Quinlin IS; Samad KA; Phillips CA; Robinson W; Dobrzanski DJ; Wright SE
Clin Immunol; 2009 Dec; 133(3):333-52. PubMed ID: 19762283
[TBL] [Abstract][Full Text] [Related]
15. Mycobacterium tuberculosis RpfE promotes simultaneous Th1- and Th17-type T-cell immunity via TLR4-dependent maturation of dendritic cells.
Choi HG; Kim WS; Back YW; Kim H; Kwon KW; Kim JS; Shin SJ; Kim HJ
Eur J Immunol; 2015 Jul; 45(7):1957-71. PubMed ID: 25907170
[TBL] [Abstract][Full Text] [Related]
16. The membrane-bound mucin Muc1 regulates T helper 17-cell responses and colitis in mice.
Nishida A; Lau CW; Zhang M; Andoh A; Shi HN; Mizoguchi E; Mizoguchi A
Gastroenterology; 2012 Apr; 142(4):865-874.e2. PubMed ID: 22202458
[TBL] [Abstract][Full Text] [Related]
17. Immunization of chimpanzees with tumor antigen MUC1 mucin tandem repeat peptide elicits both helper and cytotoxic T-cell responses.
Barratt-Boyes SM; Vlad A; Finn OJ
Clin Cancer Res; 1999 Jul; 5(7):1918-24. PubMed ID: 10430099
[TBL] [Abstract][Full Text] [Related]
18. Inducible costimulator (ICOS) is a marker for highly suppressive antigen-specific T cells sharing features of TH17/TH1 and regulatory T cells.
Vocanson M; Rozieres A; Hennino A; Poyet G; Gaillard V; Renaudineau S; Achachi A; Benetiere J; Kaiserlian D; Dubois B; Nicolas JF
J Allergy Clin Immunol; 2010 Aug; 126(2):280-9, 289.e1-7. PubMed ID: 20624644
[TBL] [Abstract][Full Text] [Related]
19. Higher susceptibility to experimental autoimmune encephalomyelitis in Muc1-deficient mice is associated with increased Th1/Th17 responses.
Yen JH; Xu S; Park YS; Ganea D; Kim KC
Brain Behav Immun; 2013 Mar; 29():70-81. PubMed ID: 23261777
[TBL] [Abstract][Full Text] [Related]
20. IL-17 suppresses the therapeutic activity of cancer vaccines through the inhibition of CD8
Dadaglio G; Fayolle C; Oberkampf M; Tang A; Rudilla F; Couillin I; Torheim EA; Rosenbaum P; Leclerc C
Oncoimmunology; 2020 May; 9(1):1758606. PubMed ID: 32923117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
